Opens in a new tab
Friday, 20 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Pancreatic Cancer

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Latest in Pancreatic Cancer

10 stories · every one Fact-Checked
Verastem Oncology’s investigational KRAS G12D inhibitor VS-7375 shows a 50% confirmed response rate in second-line pancreatic cancer.Clinical TrialsVerastem’s VS-7375 Shows 50% Response Rate in Pancreatic CancerVerastem Oncology reported a 50% confirmed objective response rate with investigational VS-7375 at 900 mg once daily in second-line KRAS G12D-mutant pancreatic cancer.14 Oct 2026 · 4 min read
Fact-Checked
Illustration of KRAS G12C-mutant pancreatic cancer cells with olomorasib targeted therapy following FDA Breakthrough Therapy designation for previously treated advanced pancreatic cancer.Health TidingsLilly Secures FDA Breakthrough Therapy Designation for Olomorasib in KRAS G12C-Mutant Advanced Pancreatic CancerThe FDA has granted Breakthrough Therapy designation to Eli Lilly’s investigational KRAS G12C inhibitor olomorasib for adults with previously treated advanced pancreatic cancer harboring a KRAS G12C mutation.…3 Aug 2026 · 3 min read
Fact-Checked
Illustration of Namodenoson oral therapy for advanced pancreatic ductal adenocarcinoma (PDAC) following positive Phase 2a clinical results accepted for presentation at ESMO Congress 2026.Health TidingsNamodenoson Shows Durable Disease Control in Advanced Pancreatic CancerCan-Fite BioPharma will present Phase 2a data for Namodenoson at ESMO 2026 after the oral A3 adenosine receptor agonist demonstrated durable disease stabilization, encouraging survival, and a favorable…20 Jul 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_p4yrmwp4yrmwp4yrHealth TidingsRevolution Medicines Advances Daraxonrasib Toward Europe After EMA Starts Phased Review for Pancreatic CancerThe EMA CHMP has initiated a phased review of Revolution Medicines’ oral RAS(ON) inhibitor daraxonrasib for pancreatic cancer, building on positive Phase 3 RASolute 302 results.7 Jul 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_p4yrmwp4yrmwp4yrClinical TrialsRevolution Medicines Reports Promising Phase 1/2 Results for Zoldonrasib Combinations in KRAS G12D Pancreatic CancerRevolution Medicines unveiled promising Phase 1/2 results for zoldonrasib‑based regimens in metastatic KRAS G12D pancreatic cancer at the 2026 ESMO GI Congress.2 Jul 2026 · 4 min read
Fact-Checked
laboratory, medical, medicine, hand, research, lab, test, doctor, equipment, scientist, woman, chemistry, science, hospital, experiment, person, technician, technology, healthcare, working, health, tube, work, research lab, blood samples, lab, lab, lab, lab, lab, scientistClinical TrialsCan-Fite Reports Durable Survival with Namodenoson in Heavily Pretreated Pancreatic Cancer, Plans Phase 2b Combination TrialCan-Fite BioPharma has released updated Phase 2a results for Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC).1 Jul 2026 · 4 min read
Fact-Checked
Revolution MedicineClinical TrialsRevMed Advances Zoldonrasib into Phase 3 Pancreatic Cancer TrialRevolution Medicines has launched patient dosing in RASolute 305, a pivotal Phase 3 study testing the RAS(ON) G12D‑selective inhibitor zoldonrasib with frontline chemotherapy in metastatic pancreatic ductal adenocarcinoma.…23 Jun 2026 · 3 min read
Fact-Checked
Wooden alphabet letters forming the word rethink on a flat, peach-colored background.Health TidingsElicio Narrows Phase 3 Focus for ELI-002 After Pancreatic Cancer Trial Reveals Benefit in R0 PatientsElicio Therapeutics reported mixed Phase 2 results for ELI-002 7P in resected KRAS-mutated pancreatic cancer.16 Jun 2026 · 3 min read
Fact-Checked
Wooden tiles spelling pancreatic cancer on blue. Health awareness concept.Clinical TrialsBicycle Therapeutics Highlights Nuzefatide Progress in Pancreatic CancerNew AACR 2026 data highlight clinical activity and tolerability of nuzefatide pevedotin, supporting its continued development in pancreatic cancer and other EphA2-expressing cancers.21 Apr 2026 · 2 min read
Fact-Checked
14258Medical DevicesNovocure Reports Encouraging Phase 2 Data for TTFields in Pancreatic CancerNovocure reported positive Phase 2 PANOVA-4 results showing TTFields therapy with atezolizumab and gemcitabine/nab-paclitaxel significantly improved disease control rate compared with historical chemotherapy outcomes in metastatic pancreatic cancer.26 Mar 2026 · 3 min read
Fact-Checked
Page 1 of 1